178 related articles for article (PubMed ID: 8847282)
1. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats.
Chen SJ; Chen YF; Meng QC; Durand J; Dicarlo VS; Oparil S
J Appl Physiol (1985); 1995 Dec; 79(6):2122-31. PubMed ID: 8847282
[TBL] [Abstract][Full Text] [Related]
2. The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats.
Chen SJ; Chen YF; Opgenorth TJ; Wessale JL; Meng QC; Durand J; DiCarlo VS; Oparil S
J Cardiovasc Pharmacol; 1997 Jun; 29(6):713-25. PubMed ID: 9234651
[TBL] [Abstract][Full Text] [Related]
3. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist.
Tilton RG; Munsch CL; Sherwood SJ; Chen SJ; Chen YF; Wu C; Block N; Dixon RA; Brock TA
Pulm Pharmacol Ther; 2000; 13(2):87-97. PubMed ID: 10799286
[TBL] [Abstract][Full Text] [Related]
4. Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats.
Eddahibi S; Raffestin B; Clozel M; Levame M; Adnot S
Am J Physiol; 1995 Feb; 268(2 Pt 2):H828-35. PubMed ID: 7864210
[TBL] [Abstract][Full Text] [Related]
5. ZD1611, an orally active endothelin-A receptor antagonist, prevents chronic hypoxia-induced pulmonary hypertension in the rat.
Bialecki RA; Fisher CS; Abbott BM; Barthlow HG; Caccese RG; Stow RB; Rumsey J; Rumsey W
Pulm Pharmacol Ther; 1999; 12(5):303-12. PubMed ID: 10545286
[TBL] [Abstract][Full Text] [Related]
6. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats.
Hill NS; Warburton RR; Pietras L; Klinger JR
J Appl Physiol (1985); 1997 Oct; 83(4):1209-15. PubMed ID: 9338430
[TBL] [Abstract][Full Text] [Related]
7. ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat.
DiCarlo VS; Chen SJ; Meng QC; Durand J; Yano M; Chen YF; Oparil S
Am J Physiol; 1995 Nov; 269(5 Pt 1):L690-7. PubMed ID: 7491990
[TBL] [Abstract][Full Text] [Related]
8. Endothelin-A receptor antagonist prevents acute hypoxia-induced pulmonary hypertension in the rat.
Oparil S; Chen SJ; Meng QC; Elton TS; Yano M; Chen YF
Am J Physiol; 1995 Jan; 268(1 Pt 1):L95-100. PubMed ID: 7840234
[TBL] [Abstract][Full Text] [Related]
9. The orally active nonpeptide selective endothelin ETA receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats.
Yuyama H; Fujimori A; Sanagi M; Koakutsu A; Sudoh K; Sasamata M; Miyata K
Eur J Pharmacol; 2004 Aug; 496(1-3):129-39. PubMed ID: 15288584
[TBL] [Abstract][Full Text] [Related]
10. Endothelin receptors blockade blunts hypoxia-induced increase in PAP in humans.
Pham I; Wuerzner G; Richalet JP; Peyrard S; Azizi M
Eur J Clin Invest; 2010 Mar; 40(3):195-202. PubMed ID: 20415698
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.
Iglarz M; Landskroner K; Bauer Y; Vercauteren M; Rey M; Renault B; Studer R; Vezzali E; Freti D; Hadana H; Schläpfer M; Cattaneo C; Bortolamiol C; Weber E; Whitby BR; Delahaye S; Wanner D; Steiner P; Nayler O; Hess P; Clozel M
J Cardiovasc Pharmacol; 2015 Nov; 66(5):457-67. PubMed ID: 26230396
[TBL] [Abstract][Full Text] [Related]
12. The endothelin antagonist bosentan: hemodynamic effects during normoxia and hypoxic pulmonary hypertension in pigs.
Holm P; Liska J; Clozel M; Franco-Cereceda A
J Thorac Cardiovasc Surg; 1996 Oct; 112(4):890-7. PubMed ID: 8873714
[TBL] [Abstract][Full Text] [Related]
13. Hypoxic pulmonary hypertension is prevented in rats with common bile duct ligation.
Imamura M; Luo B; Limbird J; Vitello A; Oka M; Ivy DD; McMurtry IF; Garat CV; Fallon MB; Carter EP
J Appl Physiol (1985); 2005 Feb; 98(2):739-47. PubMed ID: 15516365
[TBL] [Abstract][Full Text] [Related]
14. Dual endothelin receptor blockade with tezosentan markedly attenuates hypoxia-induced pulmonary vasoconstriction in a porcine model.
Hedelin P; Kylhammar D; Rådegran G
Acta Physiol (Oxf); 2012 Mar; 204(3):419-34. PubMed ID: 21726419
[TBL] [Abstract][Full Text] [Related]
15. PAF antagonists inhibit pulmonary vascular remodeling induced by hypobaric hypoxia in rats.
Ono S; Westcott JY; Voelkel NF
J Appl Physiol (1985); 1992 Sep; 73(3):1084-92. PubMed ID: 1400021
[TBL] [Abstract][Full Text] [Related]
16. Effects of U50,488H on hypoxia pulmonary hypertension and its underlying mechanism.
Li J; Zhang P; Zhang QY; Zhang SM; Guo HT; Bi H; Wang YM; Sun X; Liu JC; Cheng L; Cui Q; Yu SQ; Kaye AD; Yi DH; Pei JM
Vascul Pharmacol; 2009; 51(2-3):72-7. PubMed ID: 19351568
[TBL] [Abstract][Full Text] [Related]
17. Prevention and reversal of hypoxic pulmonary hypertension by calcium antagonists.
Stanbrook HS; Morris KG; McMurtry IF
Am Rev Respir Dis; 1984 Jul; 130(1):81-5. PubMed ID: 6742615
[TBL] [Abstract][Full Text] [Related]
18. Endothelin-A receptor blockade prevents and partially reverses neonatal hypoxic pulmonary vascular remodeling.
Ambalavanan N; Bulger A; Murphy-Ullrich J; Oparil S; Chen YF
Pediatr Res; 2005 May; 57(5 Pt 1):631-6. PubMed ID: 15774824
[TBL] [Abstract][Full Text] [Related]
19. Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function.
Pearl JM; Wellmann SA; McNamara JL; Lombardi JP; Wagner CJ; Raake JL; Nelson DP
Ann Thorac Surg; 1999 Nov; 68(5):1714-21; discussion 1721-2. PubMed ID: 10585047
[TBL] [Abstract][Full Text] [Related]
20. Endothelin blockade in angiotensin II hypertension: prevention and treatment studies in the rat.
Ficai S; Herizi A; Mimran A; Jover B
Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1100-3. PubMed ID: 11903325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
